Who is eligible for clinical trial NCT06118086?

Participants must meet the protocol's inclusion criteria for Adenoid Cystic Carcinoma. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT06118086 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma (NCT06118086)

A Phase 1/2, Multicenter, Open-label Study of REM-422, a MYB mRNA Degrader, in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma

🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Remix Therapeutics

🩺 Plain-English Summary (8th-Grade Level)

The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (23 items) and avoid the listed exclusions (22 items).

Location: University of California San Francisco Helen Diller Comprehensive Cancer Center — San Francisco, California

Age range: 18 Years

🧪 Interventions in This Study

REM-422 (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Known hypersensitivity or contraindication to any component of REM-422 or to drugs chemically related to REM-422 or its excipients.
Clinically significant active infection. Simple urinary tract infection, uncomplicated bacterial pharyngitis responding to active treatment are permitted. Participants receiving intravenous antibiotics ≤ 7 days prior to enrollment are excluded (prophylactic antibiotics, antivirals or antifungals are permitted).
Evidence of active HIV infection.
Evidence of currently active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
Primary immunodeficiency.
Current or expected need for daily systemic corticosteroid therapy ≥ 10 mg of prednisone equivalent. Topical or inhaled corticosteroids with minimal systemic absorption may enroll and continue minimal corticosteroids if the participant is on a stable dose.
Live vaccine ≤ 6 weeks prior to the start of REM-422.
Use of strong CYP3A inhibitors or CYP3A inducers
Drugs that reduce gastric acidity, such as H2-receptor antagonists (eg, ranitidine, famotidine) and proton pump inhibitors (e.g., omeprazole, esomeprazole) within 7 days prior to the initiation of REM-422 administration or during the study
Pregnancy or participants planning to become pregnant during the duration of the study, or lactation.
Participants with malabsorption syndrome, a disease significantly affecting gastrointestinal function, or resection of the stomach or bowel.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (9 Sites)

University of California San Francisco Helen Diller Comprehensive Cancer Center — San Francisco, California
Moffitt Cancer Center — Tampa, Florida
Dana Farber Cancer Research Institute — Boston, Massachusetts
University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
Memorial Sloan Kettering Cancer Center — New York, New York
Sarah Cannon Research Institute — Nashville, Tennessee
MD Anderson Cancer Center — Houston, Texas
Centre Antoine Lacassagne — Nice,
Institut de Cancerologie Gustave-Roussy — Villejuif,

📞 Contact the Study Coordinator

Phone: (781) 827-0902

Email: ClinicalTrials@remixtx.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗